AUAlessia Ugolini

Alessia Ugolini

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alessia Ugolini has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Double activation and low IL-2 manufacturing protocol increase expansion of healthy and patient derived CAR-Tregs

    by Ugolini Alessia, Miceli Anna, Bercher-Brayer Clara, Cesarano Susanna, Barbara Camisa, Carulli Pierluigi, Monti Paolo, Ramirez Giuseppe Alvise, Bonomi Elisa, Rudilosso Laura, et al.

  • T cells dressed up with a dual HLA-restricted TCR targeting cathepsin G drive effective AML eradication

    by Francesca Marzuttini, Alessia Potenza, Ludovica Celli, Anna Simioni, Laura Conte, Barbara Camisa, Zulma Irene Magnani, Lucia Sergi Sergi, Neda Mohammadi, Samantha Scaramuzza, et al.

    Despite immunosensitivity, genetic heterogeneity, low mutational burden and lack of tumor-specific antigens hinder immunotherapy success for acute myeloid leukemia (AML). T cell receptors (TCRs) offer a promising route by targeting tumor-relevant extra- and intracellular antigens shared across AML subtypes; however human leukocyte antigen (HLA) restriction limits their potential. We identified a potent TCR capable of recognizing peptides of Cathepsin G (CTSG), a serine protease confined to neutrophil granules but aberrantly localized in the cytoplasm of blasts, when presented by HLA-A*24:02 and HLA-C*07:02, highly frequent alleles. Leveraging TCR gene-editing and CD8 co-receptor transduction, we engineered a robust T cell population, comprising CD4+ CD8+ T lymphocytes with enhanced functionality, without altering subset identity. T cells expressing the CTSG-TCR exhibited strong and specific cytotoxicity against primary blasts, in vitro and in vivo. Noticeably, no alterations in peripheral blood cell populations, bone marrow hematopoiesis, or extramedullary hematopoietic organs (spleen and liver) were observed, demonstrating optimal on-target/off-tumor safety profile. Moreover, the absence of off-target cross-reactivity was proved by peptide mutagenesis, highlighting the specificity of the TCR for CTSG. These results reveal the potential of dual restricted TCRs, and of CTSG-TCR T cells as powerful therapeutics for a broad AML patient population.